Thus, FoxO1 plays a key role in the control of cardiac insulin signaling both in physiological and pathophysiological conditions, and it might prove a novel therapeutic or preventive strategy for treating individuals with DCM. This evidence concerns the gene FOXO1 and familial dilated cardiomyopathy.